// App-Quantinova.ai

BSH2020‐PO‐085 : Escalated BEACOPDac as first line therapy in 100 Hodgkin lymphoma patients reduces red cell transfusion requirements and may shorten time to menstrual period recovery whilst maintaining efficacy compared to escalated BEACOPP

Researchers

Presenter

  • A. Santarsieri

Principal Investigators

  • P. Brice

  • T. F. Menne

  • W. Osborne

  • T. Creasey

  • K. M. Ardeshna

  • S. Behan

  • S. Booth

  • G. P. Collins

  • K. Cwynarski

  • S. Iyengar

  • S. G. Jones

  • D. O'Mahony

  • N. Martinez-Calle

  • P. McKay

  • S. K. Nagumantry

  • J. F. Rudge

  • N. Shah

  • G. Stafford

  • A. Sternberg

  • B. J. Uttenthal

  • A. K. McMillan

  • G. A. Follows

Medical Centers

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Hospital Saint Antoine, Paris, France

  • Newcastle upon Tyne NHS Foundation Trust

  • Newcastle University Hospitals NHS Foundation Trust, Newcastle

  • University College London, London, UK

  • Oxford University Hospitals

  • Oxford University Hospitals NHS Trust, Oxford,

  • Royal Marsden NHS Foundation Trust, London, UK

  • Sherwood Forest Hospitals NHS Trust, Sutton‐in‐Ashfield, UK

  • Cork University Hospital, Cork, Ireland

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • The Beatson, West of Scotland Cancer Centre, Glasgow,

  • Peterborough City Hospital, Peterborough, United Kingdom

  • Bullard Laboratories, Cambridge

  • Haematology, Norfolk and Norwich University Hospital NHS Foundation Trust, London

  • Great Western Hospital, Swindon, UK

  • Nottingham City Hospital, Nottingham ,

Locations

  • United Kingdom

  • France

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved